Trials / Completed
CompletedNCT01478373
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to Imatinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dovitinib (TKI258) | Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2011-11-23
- Last updated
- 2016-04-27
- Results posted
- 2015-08-10
Locations
15 sites across 5 countries: Finland, France, Germany, Italy, Spain
Source: ClinicalTrials.gov record NCT01478373. Inclusion in this directory is not an endorsement.